{"doi":"10.1016/j.bioorg.2023.106779","title":"Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer","abstract":null,"journal":"Bioorganic Chemistry","year":2023,"id":606050,"datarank":0.4493598410330987,"base_score":2.995732273553991,"endowment":2.995732273553991,"self_citation_contribution":0.4493598410330987,"citation_network_contribution":0.0,"self_endowment_contribution":0.4493598410330987,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1555617,"name":"Menghui Wang","orcid":null,"position":1,"is_corresponding":false},{"id":1555618,"name":"Yimin Gong","orcid":null,"position":2,"is_corresponding":false},{"id":1555619,"name":"Mingli Deng","orcid":null,"position":3,"is_corresponding":false},{"id":846455,"name":"Yun Ling","orcid":"0000-0002-4289-3594","position":4,"is_corresponding":false},{"id":1030840,"name":"Qingquan Li","orcid":"0000-0003-1141-2943","position":5,"is_corresponding":false},{"id":1207040,"name":"Jianxin Wang","orcid":"0000-0002-0998-4996","position":6,"is_corresponding":false},{"id":1555620,"name":"Yaming Zhou","orcid":null,"position":7,"is_corresponding":false},{"id":1555616,"name":"Chengbin Yang","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer","abstract":"Blocking the PI3K pathway has been recognized as a promising strategy for cancer therapy. Herein, we report the discovery of novel PI3K inhibitors utilizing 7-azaindole-based fragment-oriented growth. Among them, compound FD2056 stands out as the most promising candidate, maintaining potent inhibitory activity against PI3K and enhanced CDK2 inhibition, and showing moderate selectivity among 108 kinases. In cellular assays, the inhibitor FD2056 demonstrated superior anti-proliferative profiles over reference compounds against TNBC cells and significantly increased apoptosis of MDA-MB-231 cells in a dose-dependent manner. Moreover, FD2056 showed more efficacious anti-TNBC activity than the corresponding drugs BKM120 and CYC202 at an oral dose of 15 mg/kg in the MDA-MB-231 xenograft model, inhibiting tumor growth by 43% with no observable toxic effects. All these results suggest that FD2056 has potential for further development as a promising anticancr compound, and co-targeting PI3K and CDK2 pathways may provide an alternative therapeutic strategy for the treatment of TNBC.","is_dataset_classified":null,"base_score":2.995732273553991,"endowment":2.995732273553991,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37579621","pmcid":null,"openalex_id":"https://openalex.org/W4385652198","authors":[],"funders":[{"funder_name":"National Natural Science Foundation of China","grant_id":"21971045","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"22275037","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"81874064","title":null},{"funder_name":"Natural Science Foundation of Shanghai Municipality","grant_id":"22520713700","title":null},{"funder_name":"Fudan University","grant_id":"","title":null}],"total_grants":5,"fwci":3.1557,"citation_percentile":0.92995558,"influential_citations":0,"citation_trend":[{"year":2024,"count":9},{"year":2025,"count":4},{"year":2026,"count":6}],"oa_status":"closed","license":"https://doi.org/10.15223/policy-004","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0045206823004406?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0045206823004406?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.bioorg.2023.106779","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/37579621","host_type":"repository"}],"fields_of_study":["Advanced Breast Cancer Therapies","Cancer-related Molecular Pathways","PI3K/AKT/mTOR signaling in cancer","Humans","Phosphatidylinositol 3-Kinases","Triple Negative Breast Neoplasms","Cell Proliferation","Apoptosis","Phosphoinositide-3 Kinase Inhibitors","Cell Line, Tumor","Cyclin-Dependent Kinase 2"],"mesh_terms":["Phosphoinositide-3 Kinase Inhibitors","Humans","Apoptosis","Phosphatidylinositol 3-Kinases","Cell Line, Tumor","Cell Proliferation","Cyclin-Dependent Kinase 2","Triple Negative Breast Neoplasms"],"keywords":["Triple-negative breast cancer","Chemistry","PI3K/AKT/mTOR pathway","Cancer research","Kinase","Growth inhibition","Apoptosis","Breast cancer","Cancer","Pharmacology","Biochemistry","Biology","Internal medicine","Medicine","Phosphatidylinositol 3-kinase","Cyclin-dependent Kinase","Pi3k Inhibitors","Azaindole"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T03:47:18.358283Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}